Monday, November 16, 2026

[NEWS] Pain Professionals News — Monday, November 16, 2026

[NEWS] Pain Professionals News — Monday, November 16, 2026

Pain Professionals News — Monday, November 16, 2026

Pain Professionals News — Monday, November 16, 2026. Nine news items for pain professionals this week. Several strong stories from the past two weeks did not make Thursday's edition, so this issue catches up on those as well. No new acupuncture developments surfaced since Thursday.

DEA 7-OH ORDER STILL NOT PUBLISHED — November 16, 2026

As of Monday morning, November 16, the DEA has still not published the temporary order that would put concentrated 7-hydroxymitragynine (7-OH) in Schedule I. The order could have appeared any day from Friday, November 13 onward, and it takes effect the day it is published, so today is the next day it could appear. The threshold is unchanged: products above 1 milligram of combined 7-OH and mitragynine pseudoindoxyl per gram or per milliliter, or with a mitragynine-to-7-OH ratio below 100 to 1. Natural kratom leaf is not the target, and Maryland already caps 7-OH at 2 percent of the alkaloid fraction under its own state law.

Source: Baltimore Chronicle, November 16, 2026, https://baltimorechronicle.com/health/7-oh-kratom-maryland-dea-rule/

DEA ISSUES FIRST FEDERAL REGISTRATIONS TO MORE THAN 900 MEDICAL MARIJUANA DISPENSARIES [FL] [TX] [VA] — October 30, 2026

The DEA has issued its first federal registrations to more than 900 state-licensed medical marijuana dispensaries in seven states, including Florida, Texas, and Virginia. The registrations are the first phase of the Attorney General's April 2026 order, which put qualifying state medical marijuana under Schedule III controls. Each dispensary had to pass a DEA pre-registration inspection, and the Attorney General said the regulated distribution "will help ensure broader access to chronic pain treatment." Dispensaries that applied in the April to June window but are still waiting must have a compliant supply chain in place by November 29, 2026. Recreational marijuana stays in Schedule I.

Source: FDA Law Blog, November 2026, https://www.thefdalawblog.com/2026/11/dea-issues-initial-medical-marijuana-dispensary-registrations/

INTERVENTIONAL PAIN FACES A PAY CUT IN THE 2027 FEE SCHEDULE — November 5, 2026

The International Pain and Spine Intervention Society's analysis of the 2027 Medicare Physician Fee Schedule final rule puts the impact for interventional pain at about a 2 percent decrease in allowed charges from relative value changes alone, on top of the 2.31 percent conversion factor cut for most physicians. A separate 20 percent cut applies when an office visit billed with modifier 25 is done the same day as a zero-day global procedure, paying only the highest-valued service in full. Two wins survived: CMS kept the exemption from multiple-procedure payment reductions for spinal cord stimulation and peripheral nerve stimulation procedures, and separate payment continues for qualifying non-opioid pain treatments through 2027. The traditional MIPS quality program's sunset was delayed to 2031.

Source: International Pain and Spine Intervention Society, November 5, 2026, https://www.ipsismed.org/news/738365/2027-Medicare-Payment-Updates--Impact-Analysis.htm

WEIGHT-LOSS DRUG RETATRUTIDE CUTS KNEE OSTEOARTHRITIS PAIN IN TWO PHASE 3 TRIALS — November 8, 2026

The experimental once-weekly injection retatrutide cut knee osteoarthritis pain by at least half in about two-thirds of trial participants with obesity, compared with 38 percent on placebo, in two phase 3 trials published November 8 in the New England Journal of Medicine. In the TRIUMPH-4 trial of 445 adults, pain scores fell 3.96 points on the 9 mg dose and 3.74 on 12 mg, against 2.12 on placebo, while body weight fell 20 to 24 percent. The drug is not approved by the FDA, patients who needed a knee replacement were excluded, and the trials were not designed to show whether it slows arthritis or reduces the need for surgery.

Source: New England Journal of Medicine, November 8, 2026, https://www.nejm.org/doi/abs/10.1056/NEJMoa2610676

FIRST TREATMENT FOR ACUTE LOW BACK PAIN SHAPES OVERDOSE RISK [CHIRO] [PT] — November 4, 2026

A JAMA Network Open study of 399,500 Medicaid adults with newly diagnosed acute low back pain found that the first treatment chosen predicted later opioid use disorder or overdose. Starting with higher-dose opioids (above 50 mg morphine equivalent) carried 146.6 percent higher risk, and prolonged lower-dose opioid use carried 105.2 percent higher risk, while starting with chiropractic care was linked to 32.8 percent lower risk and physical therapy to 31.1 percent lower risk. Fewer than half of patients received non-drug care first, despite guidelines recommending it. The study is observational, so it shows association, not proof that the first treatment caused the outcome.

Source: Chiropractors.Media, November 4, 2026, https://www.chiropractors.media/health-news/study-links-initial-treatment-for-acute-low-back-pain-to-opioid-use-disorder-and-overdose-

MASSAGE THERAPY IN THE VA SPOTLIGHT: RESEARCH SUPPORT, PAYMENT TROUBLE [MT] — November 10, 2026

The American Massage Therapy Association highlighted new research on Veterans Day showing massage therapy can reduce chronic pain and improve function for veterans, including a 2026 randomized trial in veterans with chronic neck pain. At the same time, the association is pressing Congress over a VA payment policy that could limit access to massage therapy. In Washington state, the dispute is already costing clinics: the state association reports 34 massage practices received combined recoupment demands of $337,139.10 from TriWest, the VA Community Care Network contractor, which is retroactively applying a Medicare multiple-procedure payment reduction to authorized services billed as far back as 2021.

Sources: American Massage Therapy Association, November 10, 2026, https://www.morningstar.com/news/pr-newswire/20261110cg94142/new-research-shows-massage-therapy-can-reduce-pain-and-improve-quality-of-life-for-veterans-and-military-service-members ; Washington State Massage Therapy Association, November 10, 2026, https://www.mywsmta.org/gr-news

ONE CHEAP PAIN PILL DRIVES CALIFORNIA WORKERS' COMP DRUG SPENDING [CA] — November 3, 2026

The generic anti-inflammatory meloxicam has become the biggest source of anti-inflammatory drug spending in California workers' compensation, rising from 1.7 percent of the group's spending in 2020 to 30.8 percent in 2025, according to the California Workers' Compensation Institute. The average payment per prescription climbed from $9 in 2020 to $92 in 2025, even though the median payment was still under $14. The gap comes from four high-cost capsule products that made up only 12.6 percent of meloxicam prescriptions but 75.7 percent of the payments, a pattern the institute says warrants close attention from payers and prescribers.

Source: California Workers' Compensation Institute, November 3, 2026, https://www.businesswire.com/news/home/20261103220564/en/

CALIFORNIA OPENS COMMENT ON MEDICAL PROVIDER NETWORK RULES [CA] — November 3, 2026

California's Division of Workers' Compensation has released its long-awaited proposed updates to the Medical Provider Network regulations, which govern the networks injured workers must use for care. A public hearing is set for Friday, December 11, 2026 at 1:00 p.m. Pacific in Oakland, and written comments are due the same day. Clinics in California networks should review the proposal now, since the rules shape which providers stay in networks and how network care is authorized.

Source: One Call, November 3, 2026, https://onecallcm.com/about/news-blog/legislative-regulatory-update-october-2026/

WEARABLE DEVICE DELAYS PAIN IN PANCREATIC CANCER — November 13, 2026

A secondary analysis of the phase 3 PANOVA-3 trial, published November 13 in JAMA Network Open, found that people with locally advanced pancreatic cancer who wore the Optune Pax device with chemotherapy went about three months longer before their pain worsened than those on chemotherapy alone: 10.1 months versus 7.4 months for general pain, and 14.7 versus 10.2 months for pancreatic cancer-specific pain. The trial enrolled 571 people. For clinics that see cancer-related pain, the result adds to the evidence that non-drug pain control can meaningfully delay worsening pain, though the device is used alongside chemotherapy, not instead of it.

Source: CURE Today, November 16, 2026, https://www.curetoday.com/view/optune-pax-delayed-pain-in-locally-advanced-pancreatic-cancer

Pain Jobs — a job board for pain management professionals.

No comments:

Post a Comment